FDA grants 510(k) approval for Propeller platform for use with Ellipta inhaler for asthma and COPD. -Propeller Health + GSK

Propeller Health, the leading digital solution for respiratory medicine, announced 510(k) clearance to market its Propeller platform for use with GSK�s Ellipta inhaler, the pharmaceutical company�s innovative, patented, dry powder inhaler (DPI). The sensor for the Ellipta inhaler was built and cleared as part of a development agreement and R&D collaboration between Propeller and GSK that was announced on December 1, 2015. This FDA clearance follows CE Mark and Health Canada registration for the device and system earlier this year.

Propeller is FDA-cleared to help patients and their physicians better understand asthma and COPD, and help to improve the symptoms and outcomes of these chronic respiratory diseases. With proprietary sensor technology, software, and services, Propeller�s digitally-guided therapy platform integrates information from multiple sources, including connected medications, then uses machine intelligence to help individuals manage their condition.